Despite the lower global DNA methylation and smaller adipocyte size observed in VAT of the HFCS offspring, site-specific DNA methylation analysis of the leptin gene promoter did not find significant alterations, suggesting that genomic loci have different degrees of susceptibility to the maternal HF and CS treatments. The gene discussed is LEP; the disease is hydrops fetalis.